ArticleJournal of global health2025
Oxidative balance score and all-cause mortality among hypertensive individuals.
Article in Journal of global health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Oxidative stress contributes to hypertension and its complications. The oxidative balance score (OBS) could therefore provide insight into the relationship with mortality in hypertensive individuals. We aimed to investigate the association between OBS and all-cause mortality using data from National Health and Nutrition Examination Survey 2007-18. Methods: Our sample comprised 11 196 hypertensive participants. We calculated OBS based on dietary and lifestyle factors and categorised participants accordingly into quartiles. We used Cox proportional hazards model to assess associations between OBS and mortality, and restricted cubic spline (RCS) analyses to determine dose-response relationships. Lastly, we conducted Kaplan-Meier survival curves and stratified/sensitivity analyses. Results: 1764 deaths occurred during a median follow-up time of 73.4 months. Higher OBS was significantly associated with lower mortality risk, whereby participants in the highest OBS quartile had a 34% reduced mortality risk compared to those in the lowest quartile (hazard ratio (HR) = 0.66; 95% confidence interval (CI) = 0.51-0.84, P = 0.001). Each unit increase in OBS reduced mortality risk by 2% (HR = 0.98; 95% CI = 0.96-0.99, P < 0.001). We observed similar results for dietary and lifestyle OBS. RCS analyses indicated a nearly linear dose-response relationship between OBS and the risk of all-cause mortality (P-value for nonlinearity >0.05). Kaplan-Meier curves confirmed better survival in those with higher OBS (log-rank P-value <0.001). Stratified analyses showed stronger protective effects in individuals with middle incomes and those without a history of cancer (P-value for interaction <0.05). Sensitivity analyses confirmed the robustness of these findings. Conclusions: Higher OBS levels, along with its dietary and lifestyle subscale scores, are significantly associated with a reduced risk of all-cause mortality among hypertensive individuals. These findings highlight the importance of oxidative balance and the potential benefits of antioxidant-rich diets and healthy lifestyles in reducing mortality risk for this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.